Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...